Efavirenz: a review

  • Vrouenraets S
  • Wit F
  • Tongeren J
 et al. 
  • 40


    Mendeley users who have this article in their library.
  • 72


    Citations of this article.


Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combination regimens is good, as has been demonstrated in many clinical trials. Efavirenz has a long plasma half-life, which allows for once-daily dosing, but, as a consequence of this and the low genetic barrier, it is also prone to select for viral resistance when adherence to therapy is suboptimal. The most frequently encountered side effects are neuropsychiatric symptoms. These side effects are usually transient, but have been shown to persist for up to 2 years after initiation of therapy in some patients. This review outlines important and recent pharmacological and clinical data, which explain why efavirenz became a component of preferred treatment regimens today.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Saskia ME Vrouenraets

  • Ferdinand WNM Wit

  • Jacqueline van Tongeren

  • Joep MA Lange

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free